Upregulation and nuclear localization of TNF-like Cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Upregulation and nuclear localization of TNF-like Cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions
Authors
Keywords
-
Journal
EXPERIMENTAL DERMATOLOGY
Volume 20, Issue 9, Pages 725-731
Publisher
Wiley
Online
2011-06-14
DOI
10.1111/j.1600-0625.2011.01304.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Constitutive TL1A (TNFSF15) Expression on Lymphoid or Myeloid Cells Leads to Mild Intestinal Inflammation and Fibrosis
- (2011) David Q. Shih et al. PLoS One
- High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis
- (2010) Giorgos Bamias et al. CLINICAL IMMUNOLOGY
- Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment
- (2010) Marjan De Groot et al. EXPERIMENTAL DERMATOLOGY
- Up-regulation of TNF-alpha secretion by cigarette smoke is mediated by Egr-1 in HaCaT human keratinocytes
- (2010) Sang Hoon Jeong et al. EXPERIMENTAL DERMATOLOGY
- The TNF-Like Protein 1A-Death Receptor 3 Pathway Promotes Macrophage Foam Cell Formation In Vitro
- (2010) J. E. McLaren et al. JOURNAL OF IMMUNOLOGY
- TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohnʼs disease
- (2009) Nobuhiko Kamada et al. INFLAMMATORY BOWEL DISEASES
- Cytokine-Producing Dendritic Cells in the Pathogenesis of Inflammatory Skin Diseases
- (2009) Leanne M. Johnson-Huang et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Key Role of Macrophages in the Pathogenesis of CD18 Hypomorphic Murine Model of Psoriasis
- (2009) Honglin Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
- (2009) Antonella Di Cesare et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
- (2009) Shinji Kagami et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis
- (2008) Giorgos Bamias et al. CLINICAL IMMUNOLOGY
- Tumor necrosis factor antagonists in the therapy of psoriasis
- (2008) Rotraut Mössner et al. CLINICS IN DERMATOLOGY
- Isolation of epidermal cells and cDNA cloning of TNF decoy receptor 3 of conger eel, Conger myriaster
- (2008) Shigeyuki Tsutsui et al. FISH & SHELLFISH IMMUNOLOGY
- TL1A (TNFSF15) Regulates the Development of Chronic Colitis by Modulating Both T-Helper 1 and T-Helper 17 Activation
- (2008) Hidetoshi Takedatsu et al. GASTROENTEROLOGY
- Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation
- (2008) Lei Fang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- TL1A–DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease
- (2008) Bhanu P. Pappu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Type I Interferon: Potential Therapeutic Target for Psoriasis?
- (2008) Yihong Yao et al. PLoS One
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started